𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

✍ Scribed by Howard, Robert; McShane, Rupert; Lindesay, James; Ritchie, Craig; Baldwin, Ashley; Barber, Robert; Burns, Alistair; Dening, Tom; Findlay, David; Holmes, Clive

Book ID
111887339
Publisher
Massachusetts Medical Society
Year
2012
Tongue
English
Weight
676 KB
Volume
366
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Memantine enhances autonomy in moderate
Memantine enhances autonomy in moderate to severe Alzheimer's disease
✍ Benoît Rive; Martine Vercelletto; Florence Delamarre Damier; John Cochran; Cléme 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract ## Background Alzheimer's disease (AD) is the leading cause of dementia and its course renders patients functionally disabled. Memantine is the first drug to demonstrate a clinical benefit in the treatment of patients with moderately‐severe to severe AD. ## Objectives Our objective w

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving